AACHEN, Germany & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) today announces that it has successfully completed a Phase I study with its intravenous sedative/anaesthetic CNS 7056. The study was completed ahead of schedule because the target criterion, more than 50% of the volunteers reaching loss of consciousness for more than 5 minutes, was reached in the 9th of the 10 planned cohorts. No serious adverse events have been reported to PAION. The company expects to report headline data of the study early in 2009, and will progress to the next stage of development rapidly thereafter.
